Roth Capital


Capstone Turbine Represents An Attractive Entry Point For LT Holders, Says Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Capstone Turbine Corp. (CPST) and a price target of $1.

TG Therapeutics Is Poised For Upside, Says Roth Capital Analyst

In a research note released today, Roth Capital reiterated coverage on TG Therapeutics, Inc. (TGTX) with a Buy rating and a price target of $15.

Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …

Palatin Technologies Reiterated With A Buy At Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Palatin Technologies, Inc. (PTN) and a price target of $6.

Roth Capital Reiterates Buy Rating for Celator Pharmaceuticals

In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …

Roth Capital Sees Downside in Dendreon Corporation Shares

In a research note issued today, Roth Capital reiterated coverage with a “Sell” rating on Dendreon Corporation (DNDN) and lowered its price target to $0.50 from …

Roth Capital Reaffirms EnteroMedics at Buy; Positive Bias Heading Into The FDA Panel

In a research note issued today, Roth Capital reiterated coverage with a “Buy” rating on EnteroMedics Inc. (ETRM), and a price target of $3.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts